

Holmusk partners with Merck to focus on diabetes & prediabetes patients in APAC

11 November 2020 | News

The goal is to help patients achieve weight loss and improved blood glucose control.



Singapore-based Holmusk has announced a collaboration with the healthcare business sector of Merck, to support patients and physicians in Asia-Pacific (APAC) with a holistic treatment approach for prediabetes and diabetes.

This partnership involves Holmusk's GlycoLeap, a leading mobile digital therapeutics platform that utilizes a highly data-driven approach to deliver personalized dietary feedback, interactive educational lessons, and 1-1 guidance with a qualified health coach. The goal is to help patients achieve weight loss and improved blood glucose control.

Lifestyle and behavior change are foundational for good management of patients with prediabetes & diabetes, yet often difficult to implement by healthcare providers due to limited resources and lack of time. Digital health solutions like GlycoLeap have the potential to track, personalize and influence patient behaviors in an effective, engaging and scalable way.

By linking patients with a personal health coach, GlycoLeap will complement medications for diabetes and prediabetes and contribute to diabetes prevention and improving chronic disease outcomes. The Diabetes Prevention Program randomized clinical trial demonstrated that lifestyle intervention and metformin therapy reduced progression to diabetes by 58 and 31%, respectively, in people at-risk of Type 2 diabetes.